论文部分内容阅读
目的:探讨二甲双胍联合西格列汀对2型糖尿病患者氧化应激、胰岛素抵抗的影响。方法:收集我院就诊或住院治疗的80例2型糖尿病患者,随机分为实验组和对照组,每组40例。两组患者入院后均给予相应的治疗措施,对照组患者给予二甲双胍250 mg/次,2次/d;实验组患者在对照组的基础上给予西格列汀100 mg/次,1次/d,治疗均连续8周。治疗结束后对患者血清丙二醛(MDA)、8异前列腺素F2α(8-iso-PGF2α)、空腹血糖(FBG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)以及患者临床治疗效果进行检测并比较。结果:与治疗前相比,治疗后两组患者MDA、8-iso-PGF2α、FBG、FINS以及HOMA-IR水平均下降(P<0.05);与对照组相比,实验组患者MDA、8-iso-PGF2α、FBG、FINS以及HOMA-IR水平较低(P<0.05),临床治疗总有效率较高(P<0.05)。结论:二甲双胍联合西格列汀能够降低2型糖尿病患者血糖水平,降低MDA、8-iso-PGF2α水平,减轻氧化应激反应,降低胰岛素抵抗,临床疗效较好。
Objective: To investigate the effects of metformin combined with sitagliptin on oxidative stress and insulin resistance in type 2 diabetic patients. Methods: Eighty patients with type 2 diabetes who were treated in our hospital or hospitalized were randomly divided into experimental group and control group, 40 cases in each group. The patients in the control group were treated with metformin 250 mg twice daily, and the patients in the control group were given sitagliptin 100 mg once daily , Treatment for 8 weeks. Serum levels of malondialdehyde (MDA), 8-iso-PGF2α, fasting blood glucose (FBG), fasting insulin (FINS), insulin resistance index (HOMA-IR) The effect is tested and compared. Results: Compared with those before treatment, the levels of MDA, 8-iso-PGF2α, FBG, FINS and HOMA-IR decreased after treatment in both groups (P < The levels of iso-PGF2α, FBG, FINS and HOMA-IR were lower (P <0.05), and the total effective rate of clinical treatment was higher (P <0.05). Conclusion: Metformin combined with sitagliptin can reduce blood glucose levels, reduce the level of MDA and 8-iso-PGF2α in type 2 diabetic patients, relieve oxidative stress and reduce insulin resistance, and have good clinical efficacy.